July 20, 2010

Cholesterol Lowering, Cardiovascular Diseases, and the Rosuvastatin – JUPITER Controversy A Critical Reappraisal

.   .   

This article critically reviews the trial JUPITER which reported a substantial decrease in the risk of cardiovascular diseases among patients without coronary heart disease and with normal or low cholesterol levels. Concern was expressed that the trial was flawed as it was discontinued (according to prespecified rules) after fewer than 2 years of follow-up, with no differences between the 2 groups on the most objective criteria. The authors concluded that the results of the trial do not support the use of statin treatment for primary prevention of cardiovascular diseases, while raising concerning questions about the role of commercial sponsors.

Related Articles:

Internal Medicine for Nephrologists

Comments are closed.